Figure 1. Changes in total/subscale Diabetes Therapy Related Quality of Life (DTR-QOL) scores from baseline to 3 months after switching. The subscale assessment covers the following four domains: domain 1, burden on social activities and daily activities; domain 2, anxiety and dissatisfaction with treatment; domain 3, hypoglycemia; and domain 4, satisfaction with treatment.

From: Improvement of Quality of Life by Switching from Oral Semaglutide to Tirzepatide in Patients with Type 2 Diabetes

Figure 2. a: Changes in glycated hemoglobin levels during the study period. b: Changes in body weight during the study period. mo: month(s).

From: Improvement of Quality of Life by Switching from Oral Semaglutide to Tirzepatide in Patients with Type 2 Diabetes

PAGE TOP